Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Canagliflozin in Advanced Renal Disease With MRI Endpoints

NCT06182839 is registered in ClinicalTrials.gov with McGill University Health Centre/Research Institute of the McGill University Health Centre as lead sponsor.

NCT NCT06182839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06182839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Canagliflozin in Advanced Renal Disease With MRI Endpoints
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2024
Completion date
March 30, 2029
Enrollment
92 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esrd, ckd stage 4, ckd stage 5